STOCK TITAN
  1. Home
  2. News
  3. CANF

Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares - CANF STOCK NEWS

Welcome to our dedicated page for Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares stock.

Can-Fite BioPharma Ltd. (symbol: CANF) is a clinical-stage biopharmaceutical company headquartered at 10 Bareket Street, פ"ת, Israel. This biotechnology firm specializes in the development of orally bioavailable small molecule therapeutic products aimed at treating a range of conditions including cancer, liver, and inflammatory diseases.

The company leverages its proprietary platform technology, which targets the Gi protein associated A3 adenosine receptor (A3AR) to develop its therapeutic candidates. One of its leading drug candidates, Piclidenoson, is currently undergoing a Phase III clinical trial for psoriasis, indicating its advanced stage in the development pipeline.

Another significant product in Can-Fite's portfolio is Namodenoson. This drug is making strides towards addressing liver-related conditions, with a Phase III trial underway for hepatocellular carcinoma (HCC), the most common form of liver cancer. Additionally, it is in a Phase IIb trial for non-alcoholic steatohepatitis (NASH), a serious liver condition with limited treatment options.

Can-Fite BioPharma is committed to improving patient outcomes through innovative therapeutic solutions. The company collaborates with various partners and research institutions to drive its drug development programs forward. Its focus on oral therapeutics provides an added advantage of ease of administration, potentially improving patient compliance and overall treatment efficacy.

This combination of advanced clinical trials, strategic partnerships, and a focused therapeutic approach highlights Can-Fite BioPharma's role as a significant player in the biopharmaceutical industry.

News

Can-Fite Reports 2023 Financial Results and Clinical Update

Rhea-AI Summary
Can-Fite BioPharma announced financial results and clinical updates for the twelve months ended December 31, 2023. Ewopharma acquired marketing rights for Namodenoson in the treatment of pancreatic carcinoma. Can-Fite broadened its IP for NASH, received a patent allowance in Canada, and published positive data for Piclidenoson in a Phase III Psoriasis study. Financially, the company reported a decrease in revenues but a decrease in net loss for the year ended December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
earnings
-
News

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Rhea-AI Summary
Can-Fite BioPharma Ltd. announces VP of Business Development to present data from pancreatic and liver cancer programs at BIO-Europe Spring 2024. Can-Fite's pipeline includes Namodenoson for liver and pancreatic cancer, licensed to various companies worldwide, attracting interest from potential partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
none
-
News

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Rhea-AI Summary
Can-Fite BioPharma Ltd. (CANF) receives a Notice of Allowance from the Canadian Intellectual Property Office for a patent related to treating fatty liver disease with Namodenoson. The company's drug reduced liver fat content, showed anti-inflammatory effects, and decreased body weight in patients with NASH in a successful Phase IIa study. Can-Fite's Namodenoson is licensed for NASH treatment in various territories, and the company also has a distribution agreement for its anti-inflammatory drug, Piclidenoson, for psoriasis treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
none
News

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Rhea-AI Summary
Can-Fite BioPharma Ltd. expands its out licensing transaction with Ewopharma AG to include the pancreatic cancer indication for Piclidenoson and Namodenoson. Ewopharma AG paid Can-Fite an upfront payment of US$2.25 million with up to an additional US$40.45 million, plus 17.5% royalties on net sales. The distribution agreement allows Ewopharma AG to market and sell the drugs in CEE countries and Switzerland. Can-Fite is pleased with the expansion and considers it an important transaction for the company's penetration into Ewopharma's territory.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
-
News

Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study

Rhea-AI Summary
Can-Fite BioPharma Ltd. announces the publication of a phase 3 clinical trial for piclidenoson in plaque psoriasis in the Journal of the European Academy of Dermatology and Venereology. The study met its primary endpoint, showing significant improvement in Psoriasis Area and Severity Index (PASI) scores. The drug demonstrated excellent safety and tolerability and is currently being evaluated in a pivotal Phase III study approved by the FDA and EMA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
clinical trial
-
News

The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

Rhea-AI Summary
Can-Fite BioPharma Ltd. (CANF) reports new data on Namodenoson's potential as an anti-obesity drug, highlighting its ability to reduce body weight and inhibit fat levels. The global obesity treatment market is projected to reach $100 billion by 2030, making Namodenoson a potential contender in this lucrative market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
News

Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan

Rhea-AI Summary
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) received a positive response from the FDA on the Pediatric Study Plan for the treatment of children suffering from psoriasis with Piclidenoson. The plan aims at registration of Piclidenoson with both the FDA and the EMA for the treatment of plaque psoriasis. There is a high market need for a safe and efficacious drug for the treatment of children who suffer from psoriasis. Can-Fite believes the inclusion of children in one or both of the Phase 3 studies significantly broadens any future market launch potential of the drug.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
-
News

Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development

Rhea-AI Summary
XYZ Pharmaceuticals (XYZ) Announces Clinical Trial to Enroll Patients for New Drug Study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
clinical trial
-
News

Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update

Rhea-AI Summary
Can-Fite BioPharma Ltd. (CANF) announced a patient in their Phase II study remains cancer-free 6.9 years after starting treatment with Namodenoson. The company reported financial results, clinical milestones, and drug development advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
earnings
News

Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds

Rhea-AI Summary
Can-Fite BioPharma Ltd. (CANF) announced a definitive agreement for the exercise of outstanding warrants to purchase up to 1,963,637 American Depositary Shares (ADSs) at a reduced exercise price of $1.53 per share. The closing of the offering is expected to occur soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.47%
Tags
none

FAQ

What is the current stock price of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)?

The current stock price of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF) is $1.48 as of December 20, 2024.

What is the market cap of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)?

The market cap of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF) is approximately 8.8M.

What does Can-Fite BioPharma Ltd. specialize in?

Can-Fite BioPharma specializes in developing orally bioavailable small molecule therapeutic products for cancer, liver, and inflammatory diseases.

Where is Can-Fite BioPharma Ltd. located?

Can-Fite BioPharma Ltd. is headquartered at 10 Bareket Street, פ"ת, Israel.

What is Piclidenoson?

Piclidenoson is a drug candidate from Can-Fite BioPharma currently in Phase III clinical trials for treating psoriasis.

What is Namodenoson used for?

Namodenoson is aimed at treating liver conditions such as hepatocellular carcinoma (HCC) and non-alcoholic steatohepatitis (NASH).

What stage are the trials for Namodenoson?

Namodenoson is in a Phase III trial for HCC and a Phase IIb trial for NASH.

What is the A3 adenosine receptor (A3AR)?

The A3 adenosine receptor (A3AR) is a therapeutic target used by Can-Fite BioPharma's platform technology for drug development.

How does Can-Fite BioPharma's technology benefit patients?

Can-Fite BioPharma's technology focuses on developing oral therapeutics, which are easier to administer, potentially improving patient compliance and treatment outcomes.

What is the significance of Can-Fite BioPharma's partnerships?

Partnerships with research institutions and other entities help Can-Fite BioPharma advance its drug development programs and bring innovative therapies to market.

Is Can-Fite BioPharma listed on any stock exchange?

Yes, Can-Fite BioPharma Ltd. is listed on NASDAQ under the symbol CANF.

What is the focus of Can-Fite BioPharma's current projects?

The current focus includes advanced clinical trials for drugs treating psoriasis, hepatocellular carcinoma (HCC), and non-alcoholic steatohepatitis (NASH).

Stock CANF logo
Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares

NYSE:CANF

CANF Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

CANF Stock Data

8.84M
6.10M
10.5%
2.27%
Biotechnology
Healthcare
Link
United States of America
Ramat Gan